Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Receivables (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Change in Receivables data on record, last reported at -$425000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables changed N/A year-over-year to -$425000.0; the TTM value through Sep 2025 reached $100000.0, changed N/A, while the annual FY2024 figure was $556000.0, 679.17% up from the prior year.
  • Change in Receivables reached -$425000.0 in Q3 2025 per CYCN's latest filing, down from -$56000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $556000.0 in Q4 2024 and bottomed at -$425000.0 in Q3 2025.
  • Average Change in Receivables over 5 years is $7692.3, with a median of -$56000.0 recorded in 2025.
  • The widest YoY moves for Change in Receivables: up 200.0% in 2022, down 200.0% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $227000.0 in 2021, then tumbled by 157.71% to -$131000.0 in 2022, then rose by 26.72% to -$96000.0 in 2023, then skyrocketed by 679.17% to $556000.0 in 2024, then crashed by 176.44% to -$425000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$425000.0 in Q3 2025, -$56000.0 in Q2 2025, and $25000.0 in Q1 2025.